Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer

Published:2013-09 Issue:9 Volume:24 Page:2390-2396
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Socinski M.A.,Okamoto I.,Hon J.K.,Hirsh V.,Dakhil S.R.,Page R.D.,Orsini J.,Yamamoto N.,Zhang H.,Renschler M.F.

Funder

Celgene Corporation, Summit, NJ

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/9/2390/13790230/mdt235.pdf

Reference26 articles.

1. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer2013Version 2

2. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations);Howlader,2012

3. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program;Cetin;Clin Epidemiol,2011

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer;JAMA Oncology;2023-10-01

2. Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis;Frontiers in Medicine;2023-07-24

3. Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study;JTO Clinical and Research Reports;2023-06

4. First‐linenab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Final results of the NEPTUN study;International Journal of Cancer;2023-03-08

5. ‘ADVANCE’ (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer;Journal of Geriatric Oncology;2023-01